Notice of Results

RNS Number : 2184J
Oxford Biomedica PLC
28 June 2011
 



OXFORD BIOMEDICA: NOTICE OF INTERIM RESULTS

 

RESULTS DATE: 31 AUGUST 2011

 

Oxford, UK - 28 June 2011: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene therapy company, today announces that it will be releasing its interim results for the six months ended 30 June 2011 on Wednesday 31 August 2011.

 

An analyst briefing will be held at 11:00am GMT on Wednesday 31 August 2011 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.

 

Simultaneously to the analyst briefing at 11:00am GMT, there will be a live audio webcast of the presentation.  To connect to the webcast facility, please visit the Company's website: www.oxfordbiomedica.co.uk approximately 10 minutes (10:50am GMT) before the start of the briefing.  A replay will be made available shortly after the presentation.

 

-Ends-

 

For further information, please contact:


Oxford BioMedica plc:

Lara Mott, Head of Corporate Communications

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Emma Thompson/Katja Toon

M:Communications

 

Tel: +44 (0)20 7920 2342

 

 

Notes to editors

 

1. Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs.  The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy.  Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include Sanofi, Sigma-Aldrich and Pfizer.  Further information is available at www.oxfordbiomedica.co.uk.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NORFMGZVLNMGMZM